Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 3/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | LDHA | P00338 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | CA5A | P35218 | 1/20 | 0.54 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | PPARD | Q03181 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11214407 | 0.87 | LMNA (0.51) | LMNAHTTNPC1GAAKMT2A | |
| SCHEMBL11217489 | 0.86 | MEN1 (0.56) | LMNAHTTNPC1GAAKMT2A | |
| SCHEMBL1031036 | 0.86 | ALDH1A1 (0.73) | LMNAGAAALDH1A1MAPK1TSHR | |
| SCHEMBL30859524 | 0.85 | LMNA (0.63) | LMNAHTTNPC1GAAKMT2A | |
| SCHEMBL11187045 | 0.85 | LMNA (0.63) | LMNAHTTNPC1GAAKMT2A | |
| SCHEMBL11219331 | 0.83 | CA5A (0.53) | LMNAHTTNPC1GAAKMT2A | |
| SCHEMBL1033641 | 0.83 | LMNA (0.61) | LMNAHTTNPC1GAAKMT2A | |
| SCHEMBL187562 | 0.83 | LMNA (0.61) | LMNAHTTNPC1GAAKMT2A | |
| SCHEMBL153055 | 0.83 | GAA (0.74) | LMNAHTTNPC1GAAKMT2A | |
| SCHEMBL29602721 | 0.83 | LMNA (0.61) | LMNAHTTNPC1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006087718-A1 | EXTENSION OF LIFESPAN WITH DRUGS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2006-08-24 | — | — | WO | claimed |
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | claimed |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | claimed |
| WO-2004018428-A1 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | claimed |
| WO-2004018461-A2 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | claimed |
| EP-1902717-A2 | Vasopressin antagonist and oxytocin antagonist | Otsuka Pharmaceutical Company, Limited (JP) | 2008-03-26 | — | — | EP | disclosed |
| EP-0620003-B1 | VASOPRESSIN ANTAGONIST AND OXYTOCIN ANTAGONIST | OTSUKA PHARMA CO LTD (JP) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006087718-A1 | EXTENSION OF LIFESPAN WITH DRUGS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2006-08-24 | — | — | WO | disclosed |
| US-5753644-A | Vasopressin antagonist and oxytocin antagonist | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1998-05-19 | — | — | US | disclosed |
| US-5622947-A | VASODILATORS, HYPOTENSIVE AGENTS, DIURETICS, PLATELET AGGLUTINATION INHIBITORS; ALSO USED TO PREVENT PREMATURE BIRTH, TREAT DYSMENORRHEA | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-04-22 | — | — | US | disclosed |
| EP-0758317-A1 | N-SULPHONYL AND N-SULPHINYL AMINO ACID AMIDES AS MICROBIOCIDES | Novartis AG (CH) | 1997-02-19 | — | — | EP | disclosed |
| WO-1995030651-A1 | N-SULPHONYL AND N-SULPHINYL AMINO ACID AMIDES AS MICROBIOCIDES | CIBA-GEIGY AG (CH) | 1995-11-16 | — | — | WO | disclosed |
| US-4301280-A | Preparation of 3-substituted cephalosporins | LILLY INDUSTRIES LIMITED (GB) | 1981-11-17 | — | — | US | disclosed |
| EP-0019401-A1 | Process for preparing enamine derivatives, compounds so produced and process for preparing a 3-hydroxy-cephalosporin | Lilly Industries Limited (GB) | 1980-11-26 | — | — | EP | disclosed |
| US-4176231-A | Process for preparing 3-exomethylenecepham sulfoxides | LILLY INDUSTRIES LIMITED (GB) | 1979-11-27 | — | — | US | disclosed |
| US-4144391-A | REPLACING AN ACETOXY GROUP BY A SULFUR NUCLEOPHILE | ELI LILLY AND COMPANY (US) | 1979-03-13 | — | — | US | disclosed |
| US-4048160-A | Process for preparation of 7-alkoxy-3-bromomethylcephems | ELI LILLY AND COMPANY (US) | 1977-09-13 | — | — | US | disclosed |
| US-4048163-A | Process for preparation of 7-alkoxy-3-chloromethylcephems | ELI LILLY AND COMPANY (US) | 1977-09-13 | — | — | US | disclosed |
| US-4042585-A | Process for preparation of 3-halomethylcephems | ELI LILLY AND COMPANY (US) | 1977-08-16 | — | — | US | disclosed |
| US-4038275-A | PROCESS FOR PREPARATION OF 3-HYDROXYMETHYLCEPHEMS | ELI LILLY AND COMPANY (US) | 1977-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | LMNA 4062/4885HTT 2287/4885NPC1 3891/4885 |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | LMNA 3376/4885HTT 1599/4885NPC1 3778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.